Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 9Anus Neoplasms 2Rectal Neoplasms 1HIV Infections 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Colonic Polyps 1Colonic Neoplasms 1Colitis, Ulcerative 1Anal Canal Carcinoma 1

Interventions

Mitomycin 5Specimen Handling 4Nivolumab 4Magnetic Resonance Spectroscopy 4Fluorouracil 4Capecitabine 4Biopsy 4pembrolizumab 3Drug Therapy 3dehydroftorafur 2Vaccines 2Sigmoidoscopy 2Radiotherapy, Intensity-Modulated 2Radiation 2Proctoscopy 2Mitozytrex 2Fluorodeoxyglucose F18 2Colonoscopy 2tislelizumab 1spartalizumab 1entinostat 1durvalumab 1bintrafusp alfa protein, human 1X-Rays 1Watchful Waiting 1Vaccines, Synthetic 1Tomography, X-Ray Computed 1Taxes 1Surveys and Questionnaires 1Sentinel Lymph Node Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Anus Neoplasms × Colonoscopy × Clear all
NCT03233711 2026-05-29

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
344 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

NCT04929028 2026-05-13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Gastrointestinal

Anus Neoplasms, Rectal Neoplasms, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡